Development of an Anti-Egfr/Anti-Cd3/Anti-Mpeg Trispecific Antibody to Synergistically Enhance the Anti-Cancer Efficacy of Immuno-Enhancing Drug-Loaded Mpeg-Nanocarriers and T Cells in Tumor Microenvironment of Colorectal Cancer( II )

Project: A - Government Institutionb - National Science and Technology Council

Project Details

Description

本計畫所發展之三功能抗體可引導裝載免疫增敏劑之新型奈米藥物和患者體內T細胞準確攻擊腫瘤細胞,並將腫瘤微環境改善成有利於抗癌T細胞,以整合奈米藥物及T細胞療法之優勢,為大腸癌患者提供一種高抗癌功效且低副作用的協同性免疫化學療法。
StatusFinished
Effective start/end date8/1/217/31/22

Keywords

  • Methoxy polyethylene glycol conjugated nanoparticles (mPEG-NPs)
  • T cell immunotherapy
  • anti-EGFR/anti-CD3/anti-mPEG tri-specific antibody (TsAb)
  • novel immune-enhancing drug (Ganetespib)-loaded mPEG-NPs
  • synergistic immunochemotherapy
  • colorectal cancer